Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.

Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, Fein E, Findling RL, Calabrese JR.

J Affect Disord. 2012 Feb;136(3):1164-73. doi: 10.1016/j.jad.2011.06.033. Epub 2011 Jul 22.

2.

PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.

Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, Calabrese JR.

CNS Drugs. 2014 Jun;28(6):571-81. doi: 10.1007/s40263-014-0158-2.

3.

Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.

Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S.

Psychoneuroendocrinology. 2013 Jun;38(6):767-76. doi: 10.1016/j.psyneuen.2012.08.010. Epub 2012 Sep 19.

PMID:
22999261
4.

Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.

Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, Ghaleiha A, Akhondzadeh S.

Depress Anxiety. 2015 Mar;32(3):167-73. doi: 10.1002/da.22340. Epub 2015 Jan 23.

PMID:
25620378
5.
6.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
7.

Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.

Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA.

J Clin Psychiatry. 2010 Oct;71(10):1363-70. doi: 10.4088/JCP.09m05900gry. Epub 2010 Jul 27.

PMID:
20673554
8.

Novel Augmentation Strategies in Major Depression.

Martiny K.

Dan Med J. 2017 Apr;64(4). pii: B5338. Review.

PMID:
28385173
9.

Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response.

Lin KW, Wroolie TE, Robakis T, Rasgon NL.

Psychiatry Res. 2015 Dec 30;230(3):846-52. doi: 10.1016/j.psychres.2015.10.013. Epub 2015 Oct 22.

10.

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.

Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Rabbia M, Parkar N, Fontoura P, Santarelli L.

JAMA Psychiatry. 2016 Jul 1;73(7):675-84. doi: 10.1001/jamapsychiatry.2016.0838.

PMID:
27304433
11.

Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.

Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD.

J Affect Disord. 2014;167:368-75. doi: 10.1016/j.jad.2014.06.001. Epub 2014 Jun 11.

PMID:
25046624
12.

Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.

Vu A, Kosmiski LA, Beitelshees AL, Prigeon R, Sidhom MS, Bredbeck B, Predhomme J, Deininger KM, Aquilante CL.

Pharmacotherapy. 2016 Mar;36(3):252-62. doi: 10.1002/phar.1713. Epub 2016 Feb 29.

PMID:
26822630
13.

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S.

Neuropsychopharmacology. 2012 Aug;37(9):2093-100. doi: 10.1038/npp.2012.58. Epub 2012 May 2.

14.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
15.

Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.

Oakes TM, Dellva MA, Waterman K, Greenbaum M, Poppe C, Goldberger C, Ahl J, Perahia DG.

Curr Med Res Opin. 2015 Jun;31(6):1179-89. doi: 10.1185/03007995.2015.1037732. Epub 2015 May 6.

PMID:
25894953
16.

Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial.

Calabrese JR, Frye MA, Yang R, Ketter TA; Armodafinil Treatment Trial Study Network.

J Clin Psychiatry. 2014 Oct;75(10):1054-61. doi: 10.4088/JCP.13m08951.

PMID:
25099397
17.
18.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
19.

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG.

J Clin Psychiatry. 2006 Jun;67(6):865-73.

PMID:
16848645
20.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641

Supplemental Content

Support Center